kabutan

SanBio Company Limited(4592) Summary

4592
TSE Growth
SanBio Company Limited
1,907
JPY
-70
(-3.54%)
Apr 30, 10:16 am JST
11.91
USD
Apr 29, 9:16 pm EDT
Result
PTS
outside of trading hours
1,906.1
Apr 30, 10:15 am JST
Summary Chart Historical News Financial Result
PER
PBR
11.2
Yield
ー%
Margin Trading Ratio
159.54
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
1,945 JPY 12.14 USD
Previous Close Apr 28
1,977 JPY 12.41 USD
High Apr 30, 9:00 am
1,951 JPY 12.18 USD
Low Apr 30, 9:17 am
1,887 JPY 11.78 USD
Volume
376,500
Trading Value
0.72B JPY 4.49M USD
VWAP
1910.07 JPY 11.92 USD
Minimum Trading Value
190,700 JPY 1,191 USD
Market Cap
0.15T JPY 0.93B USD
Number of Trades
945
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
High
1-Year Average
6,952
1-Year High Oct 17, 2025
46,775
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 500 5,839,700 11679.40
Apr 17, 2026 4,100 5,735,700 1398.95
Apr 10, 2026 600 6,077,200 10128.67
Apr 3, 2026 9,800 6,109,700 623.44
Mar 27, 2026 10,200 6,363,900 623.91
Company Profile
SanBio Company Limited is a biotech venture specializing in the development of regenerative cell therapies. Their products show promise for treating neurological disorders.
Sector
Pharmaceuticals
SanBio Company Limited is a biotech venture primarily focused on the research and development of regenerative cell medicines. Founded in the United States, the company later expanded into Japan. Their flagship product, SB623, is an allogeneic neural regenerative cell therapy targeting central nervous system disorders. The company has submitted a regulatory application in Japan for chronic traumatic brain injury and aims to expand its indications to include stroke and intracerebral hemorrhage. SanBio possesses proprietary cell culture and manufacturing technologies and has secured product supply rights. Given SB623's strong neuroprotective properties, the company is also exploring its potential in other conditions such as retinal diseases. SanBio employs a business model that combines in-house development with licensing agreements with partner companies. The company places a strong emphasis on securing intellectual property rights and is pursuing a business strategy with global expansion in mind.